LDTs Rule Update: More Support for Legal Challenges Against FDA
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
The latest regulatory, legal, compliance, and technology news for labs and pathology practices.
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
Ventura County’s organized health system and three medical care providers were accused of falsely billing Medi-Cal.
New Short-read Transpore Rapid Karyotyping test can identify fetal chromosomal abnormalities in a variety of samples.
Technology can make it possible for labs and other healthcare providers to boost revenue while still providing a positive patient experience.
Federal enforcers and whistleblowers home in on billing of medically unnecessary sleep tests.
A recent study shows that the proportion of undiagnosed diabetes has dropped over the past three decades, but certain groups are more affected.
A new rule proposed by the agency would also mean new fees for follow-up and complaint surveys.
In key enforcement actions announced over the last week, a Texas-based owner faces 60 months behind bars for defrauding Medicare.
The agency is recommending repeat testing with at home COVID-19 antigen tests, regardless of actual symptoms.
The VALID Act for FDA regulation of laboratory developed tests is working its way through the final stages of the legislative process, but not everyone is loving it.
OIG says the agency is leaving millions of dollars on the table, but CMS doesn’t want to hear it.